MBX-8025
 | |
| Systematic (IUPAC) name | |
|---|---|
| {2-methyl-4-[5-methyl-2-(4-trifluoromethyl-phenyl)-2H-[1,2,3]triazol-4-ylmethylsylfanyl]-phenoxy}-acetic acid[1] | |
| Clinical data | |
| |
| |
| Identifiers | |
| PubChem | CID 11539381 |
| ChemSpider | 9714160 |
| Chemical data | |
| Formula | C20H18F3N3O3S |
| 437.435 | |
|
SMILES
| |
| |
MBX-8025 is a PPARδ receptor agonist that is being investigated for drug use by Metabolex.[2][3] According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis. The compound, formerly known as RWJ-800025, was licensed from Janssen Pharmaceutica NV.[4]
See also
References
- ↑ Zhu, F.; Han, L.; Zheng, C.; Xie, B.; Tammi, M. T.; Yang, S.; Wei, Y.; Chen, Y. (2009). "What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets". Journal of Pharmacology and Experimental Therapeutics 330 (1): 304–315. doi:10.1124/jpet.108.149955. PMID 19357322.
- ↑ Billin, A. N. (2008). "PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: An adopted orphan still looking for a home". Expert Opinion on Investigational Drugs 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307.
- ↑ Bays, H. E.; Schwartz, S.; Littlejohn, T.; Kerzner, B.; Krauss, R. M.; Karpf, D. B.; Choi, Y. -J.; Wang, X.; Naim, S.; Roberts, B. K. (2011). "MBX-8025, A Novel Peroxisome Proliferator Receptor- Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin". Journal of Clinical Endocrinology & Metabolism 96 (9): 2889. doi:10.1210/jc.2011-1061.
- ↑ "Targeting Mixed Dyslipidemia and Metabolic Syndrome".